2841 related articles for article (PubMed ID: 29770138)
1. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
2. [NY-ESO-1 and cancer immunotherapy].
Peng JR; Leng XS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
[TBL] [Abstract][Full Text] [Related]
3. Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers.
Park TS; Groh EM; Patel K; Kerkar SP; Lee CC; Rosenberg SA
J Immunother; 2016 Jan; 39(1):1-7. PubMed ID: 26641256
[TBL] [Abstract][Full Text] [Related]
4. Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.
Raza A; Merhi M; Inchakalody VP; Krishnankutty R; Relecom A; Uddin S; Dermime S
J Transl Med; 2020 Mar; 18(1):140. PubMed ID: 32220256
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.
Odunsi K; Matsuzaki J; James SR; Mhawech-Fauceglia P; Tsuji T; Miller A; Zhang W; Akers SN; Griffiths EA; Miliotto A; Beck A; Batt CA; Ritter G; Lele S; Gnjatic S; Karpf AR
Cancer Immunol Res; 2014 Jan; 2(1):37-49. PubMed ID: 24535937
[TBL] [Abstract][Full Text] [Related]
6. New York esophageal squamous cell carcinoma-1 and cancer immunotherapy.
Esfandiary A; Ghafouri-Fard S
Immunotherapy; 2015; 7(4):411-39. PubMed ID: 25917631
[TBL] [Abstract][Full Text] [Related]
7. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
8. NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.
Griffiths EA; Srivastava P; Matsuzaki J; Brumberger Z; Wang ES; Kocent J; Miller A; Roloff GW; Wong HY; Paluch BE; Lutgen-Dunckley LG; Martens BL; Odunsi K; Karpf AR; Hourigan CS; Nemeth MJ
Clin Cancer Res; 2018 Mar; 24(5):1019-1029. PubMed ID: 28947565
[No Abstract] [Full Text] [Related]
9. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.
Chou J; Voong LN; Mortales CL; Towlerton AM; Pollack SM; Chen X; Yee C; Robbins PF; Warren EH
J Immunother; 2012; 35(2):131-41. PubMed ID: 22306901
[TBL] [Abstract][Full Text] [Related]
10. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.
Maio M; Coral S; Sigalotti L; Elisei R; Romei C; Rossi G; Cortini E; Colizzi F; Fenzi G; Altomonte M; Pinchera A; Vitale M
J Clin Endocrinol Metab; 2003 Feb; 88(2):748-54. PubMed ID: 12574209
[TBL] [Abstract][Full Text] [Related]
11. Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.
Nicholaou T; Ebert L; Davis ID; Robson N; Klein O; Maraskovsky E; Chen W; Cebon J
Immunol Cell Biol; 2006 Jun; 84(3):303-17. PubMed ID: 16681828
[TBL] [Abstract][Full Text] [Related]
12. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.
Szender JB; Papanicolau-Sengos A; Eng KH; Miliotto AJ; Lugade AA; Gnjatic S; Matsuzaki J; Morrison CD; Odunsi K
Gynecol Oncol; 2017 Jun; 145(3):420-425. PubMed ID: 28392127
[TBL] [Abstract][Full Text] [Related]
13. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy.
Kohli K; Yao L; Nowicki TS; Zhang S; Black RG; Schroeder BA; Farrar EA; Cao J; Sloan H; Stief D; Cranmer LD; Wagner MJ; Hawkins DS; Pillarisetty VG; Ribas A; Campbell J; Pierce RH; Kim EY; Jones RL; Riddell SR; Yee C; Pollack SM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963013
[TBL] [Abstract][Full Text] [Related]
14. Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy.
Zhang Y; Zhang Y; Zhang L
J Cancer Res Clin Oncol; 2019 Feb; 145(2):281-291. PubMed ID: 30656409
[TBL] [Abstract][Full Text] [Related]
15. A novel era of cancer/testis antigen in cancer immunotherapy.
Meng X; Sun X; Liu Z; He Y
Int Immunopharmacol; 2021 Sep; 98():107889. PubMed ID: 34174699
[TBL] [Abstract][Full Text] [Related]
16. Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy.
Bodey B
Expert Opin Biol Ther; 2002 Aug; 2(6):577-84. PubMed ID: 12171503
[TBL] [Abstract][Full Text] [Related]
17. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
[TBL] [Abstract][Full Text] [Related]
19. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Ishihara M; Tono Y; Miyahara Y; Muraoka D; Harada N; Kageyama S; Sasaki T; Hori Y; Soga N; Uchida K; Shiraishi T; Sato E; Kanda H; Mizuno T; Webster GA; Ikeda H; Katayama N; Sugimura Y; Shiku H
Cancer Immunol Immunother; 2020 Apr; 69(4):663-675. PubMed ID: 31980914
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ.
Fujii SI; Yamasaki S; Hanada K; Ueda S; Kawamura M; Shimizu K
Cancer Sci; 2022 Mar; 113(3):864-874. PubMed ID: 34971473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
